Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2013

View Archived Issues

Researchers uncover the mechanism behind malaria parasite sensitivity to spiroindolone-based drugs

Alemtuzumab treatment maintains efficacy in phase III extension study

Sernova receives Canadian funding for Sertolin technology

Pharmacodynamics of new rituximab biosimilar evaluated

Chinese researchers present new protein kinase inhibitors for cancer

Biovista and Dart Therapeutics enter collaboration

Researchers evaluate inflammatory and immune system biomarkers in chronic prostatitis

Omeros set to advance lead PDE10 inhibitor to phase II

Myriad Genetics to conduct HRD testing for PharmaMar

NICE recommends two treatments for lung infection in cystic fibrosis

Oncodesign to apply Nanocyclix technology to Sanofi kinase target

GNbAC-1 is safe and well tolerated in phase IIa trial

University of New Mexico to collaborate with Biosortia Pharmaceuticals

Soligenix cleared to begin phase II study of SGX-942

CureVac commences phase IIb trial of mRNA-based prostate cancer vaccine

A team of German researchers disclose novel antimalarial agents

Eisai obtains FDA approval for new formulation of AcipHex

Single nucleotide polymorphisms in MKL1 and CYP3A5 genes are associated with risk of CI-AKI

KU-046 improves cognitive function in vivo

Anaeropharma Science begins first-in-human trial of APS-001-F

Anthera Pharmaceuticals begins phase III CHABLIS-SC1 trial in lupus

Both primary endpoints met in pivotal study of Androxal

Novel phosphodiesterase inhibitors patented by Lundbeck

Japanese scientists design new ACC2 inhibitors

Novel Mnk1 inhibitors identified at Bayer

Invokana approved by the FDA for type 2 diabetes

NDA filed for hepatitis C candidate simeprevir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...